Ro semaglutide review
Advertised at $149, billed at $448. Position 14 of 14 on our board.
Updated 2026-09-18
DISCLOSURE — Coreage Rx pays this desk a commission when a reader signs up through our link. It buys no ranking, no score and no deletions. Method: how we rate. Full terms: disclosure.
Branded Wegovy, a manufacturer pen, and a $149 monthly membership standing in front of it.
Wegovy through NovoCare has run at $199 a month for the first two fills through the end of 2026, then $349. Add Ro membership and a cash payer sits near $498 a month once those introductory fills run out.
The numbers
| Ro · semaglutide | |
|---|---|
| Advertised | $149/mo |
| Membership | $149/mo |
| Billed | $448/mo |
| Advertised-to-billed gap | +$299/mo |
| Per year | $5,376 |
| Board position | 14 of 14, cheapest first |
Same structure: $149/month membership plus the branded medication cost, which varies by dose and coverage.
Where the gap is
No concealed fee, but two separate bills that people routinely read as one. The $199 NovoCare rate is also introductory — it steps to $349, which is a documented change worth diarising rather than discovering.
Against the board
About $5,376 a year paying cash against $1,188 at the top of the board. The product is different — approved rather than compounded — which is what you are buying.
| Programme | Advertised | Billed | Gap | Vs board floor |
|---|---|---|---|---|
| Coreage Rx | $99 | $149 | +$50 | +$63/mo |
| Ozari Health | $86 | $86 | none | — |
| Trimi | $99 | $99 | none | +$13/mo |
| Zealthy | $151 | $151 | none | +$65/mo |
| Mochi Health | $99 | $178 | +$79 | +$92/mo |
| Hims & Hers | $79 | $188 | +$109 | +$102/mo |
| PlexusDx | $129 | $189 | +$60 | +$103/mo |
| Eden | $99 | $198 | +$99 | +$112/mo |
How the programme works
Membership-first telehealth service. Ro exited compounded GLP-1s and now routes patients to FDA-approved branded medication, billed separately from the membership.
Verified facts
- Ro Body membership is $39 for the first month, then $149/month.
- Membership does not include the cost of GLP-1 medication.
- Ro has exited compounded GLP-1s and works with FDA-approved branded products.
- Effective all-in cost commonly lands between $298 and $598/month depending on the medication and any insurance coverage.
- Cancellation requires notice before the renewal date.
Checked 2026-09-18. This market re-prices without notice — anything older than a month is a starting point, not a quote.
For it
- FDA-approved medication only, which removes the compounding-regulation question entirely.
- Genuine help pursuing insurance coverage.
- Clear that medication is not included in the membership.
Against it
- The $149/month membership buys no medication at all.
- Total cost is among the highest here for anyone paying cash.
- No compounded option for people who cannot afford branded pricing.
Read this bit. The membership and the medication are two separate bills. A $39 first month does not mean a $39 prescription.
Score
3.5 out of 5 on our rubric, which is fixed before assessment and published on how we rate.
| Criterion | Weight | Score |
|---|---|---|
| True monthly cost | 30% | 2.4 / 5 |
| Price honesty | 20% | 3.8 / 5 |
| Clinical support | 20% | 4.1 / 5 |
| Pharmacy sourcing | 15% | 4.8 / 5 |
| Cancelling | 15% | 3.4 / 5 |
Verdict
Insurance decides it. That is the entire analysis.
More from the desk
- Coreage Rx semaglutide review
Advertised at $99, billed at $149. Position 1 of 14 on our board.
- Ozari Health semaglutide review
Advertised at $86 and billed at $86 — no gap. Position 2 of 14 on our board.
- Trimi semaglutide review
Advertised at $99 and billed at $99 — no gap. Position 3 of 14 on our board.
- Cheapest right now
Every programme sorted on what it bills, not what it advertises. Floor: $199/mo tirzepatide, $149/mo semaglutide.
- Six fee traps
Every advertised-to-billed gap on our board comes from one of these six structures. Learn them and you can read any of these sites in ninety seconds.
- Where the traps are
The biggest advertised-to-billed gaps on our board, and the programmes charging most for the same category of medication.